Protein-lipid film (fuzhu) prepared from soymilk: Effects of soymilk convection on its formation, composition, and quality

The present work is focused on the preparation and in vitro release kinetics of liposomal formulation of Leuprolide Acetate. In this work, “Thin Lipid Film Hydration Method” was used for preparation of Leuprolide Acetate loaded liposomes. Prepared liposomal formulations of Leuprolide acetate was evaluated by drug entrapment study, in-vitro drug release kinetics and stability studies. The percentage drug entrapment of Leuprolide acetate for F1 and F2 formulations were found to be 78.14 ± 0.67 and 66.70 ± 0.81% respectively. In-vitro drug release study of liposomal formulations had shown zero order release pattern. Regression co-efficient (R2) value of Zero order kinetics for F1 and F2 formulations were 0.9912 and 0.9676 respectively. After storing formulations for 1 month, stability testing was done at 40C.It was found that all batches were stable. These liposomal formulations of Leuprolide acetate can be formulated for parenteral application to treat prostate cancer and in women, to treat symptoms of endometriosis (overgrowth of uterine lining outside of the uterus) or uterine fibroids.

Download Full-text

lipid film

IUPAC Compendium of Chemical Terminology ◽

10.1351/goldbook.l03570 ◽

2008 ◽

Keyword(s):

Lipid Film

Download Full-text

Ion Channel Switch- and Lipid Film-Based Biosensors

Series in Sensors - Portable Biosensing of Food Toxicants and Environmental Pollutants ◽

10.1201/b15589-8 ◽

2013 ◽

pp. 197-230

Author(s):

Tibor Hianik ◽

Dimitrios Nikolelis ◽

Georgia-Paraskevi Nikoleli

Keyword(s):

Ion Channel ◽

Lipid Film

Download Full-text

Electrochemistry inside a lipid film: fine tuning of the redox potentials of an amphiphilic viologen in phosphatidylcholine films

Journal of the Chemical Society Chemical Communications ◽

10.1039/c39900001698 ◽

1990 ◽

pp. 1698 ◽

Cited By ~ 1

Author(s):

Mel Han ◽

Angel E. Kaifer

Keyword(s):

Fine Tuning ◽

Redox Potentials ◽

Lipid Film

Download Full-text

Abstract T P99: Development of Liposomes Loaded With Computed Tomogratphy Contrast Agent for Thrombus Imaging

Stroke ◽

10.1161/str.46.suppl_1.tp99 ◽

2015 ◽

Vol 46 (suppl_1) ◽

Author(s):

Stepan Koudelka ◽

Petra Cimflova ◽

Jaroslav Turanek ◽

Robert Mikulik

Keyword(s):

Contrast Agent ◽

Size Distribution ◽

Surrounding Tissue ◽

Molar Ratio ◽

Preparation Technology ◽

Lipid Film ◽

Thrombus Imaging ◽

Novel Approach ◽

Ct Contrast Agent

Introduction: Liposomes are the most established nanocarriers that can be loaded with contrast agents as well as tailored for targeting to the desired tissue. Targeted CT liposomes represent a novel approach for rapid thrombus imaging. They allow specific and selective accumulation in thrombus providing significant contrast enhancement (expressed as HU) over the surrounding tissue. Hypothesis: We hypothesize that preparation technology will produce homogenous liposomes with sufficient level of loaded CT contrast agent. Methods: Liposomes were composed of distearoyl phosphatidylcholine, cholesterol, and distearoyl phosphatidylethanolamine - polyethylene glycol 2000 (molar ratio, 55/45/5). CT liposomes were prepared by lipid film hydration with iohexol (Omnipaque 350, GE Healthcare) followed by freeze-thaw extrusion (100 nm). Subsequently, they were purified by dialysis (Slide-A-Lyzer, cut-off 10 kDa) to remove un-loaded ioxehol. After purification, liposome-associated iohexol was determined by UV/VIS spectrophotometry and CT. Size distribution of final CT liposomes was assessed by dynamic light scattering. Results: Preparation technology produced homogenous liposome population having appropriate size distribution (90-110 nm and PD index, 0.05-0.10). Iohexol that remains associated in final CT liposomes represented only 5% of its initial level entering the preparation process. Almost 95% of iohexol was released and its final content was found to be 5 mg iodine/ml. Conclusions: Liposomal CT formulation was prepared with satisfactory size distribution and homogenity. Although the significant portion of iohexol was released, these CT liposomes were still detectable in vitro by CT. This basic liposomal platform will be optimized to achieve higher iohexol loading and will be further developed for thrombus imaging such as targeted CT liposomes.

Download Full-text

Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b

Pharmaceutics ◽

10.3390/pharmaceutics12121237 ◽

2020 ◽

Vol 12 (12) ◽

pp. 1237

Author(s):

Signe Tandrup Schmidt ◽

Dennis Christensen ◽

Yvonne Perrie

Keyword(s):

Large Scale ◽

Colloidal Stability ◽

Scale Up ◽

Cationic Liposome ◽

Poly I:C ◽

Particle Sizes ◽

Adjuvant Activity ◽

Lipid Film ◽

Gmp Production

Subunit vaccines require particulate adjuvants to induce the desired immune responses. Pre-clinical manufacturing methods of adjuvants are often batch dependent, which complicates scale-up for large-scale good manufacturing practice (GMP) production. The cationic liposomal adjuvant CAF09b, composed of dioctadecyldimethylammonium bromide (DDA), monomycoloyl glycerol analogue 1 (MMG) and polyinosinic:polycytidylic acid [poly(I:C)], is currently being clinically evaluated in therapeutic cancer vaccines. Microfluidics is a promising new method for large-scale manufacturing of particle-based medicals, which is scalable from laboratory to GMP production, and a protocol for production of CAF09b by this method was therefore validated. The influence of the manufacture parameters [Ethanol] (20–40% v/v), [Lipid] (DDA and MMG, 6–12 mg/mL) and dimethyl sulfoxide [DMSO] (0–10% v/v) on the resulting particle size, colloidal stability and adsorption of poly(I:C) was evaluated in a design-of-experiments study. [Ethanol] and [DMSO] affected the resulting particle sizes, while [Lipid] and [DMSO] affected the colloidal stability. In all samples, poly(I:C) was encapsulated within the liposomes. At [Ethanol] 30% v/v, most formulations were stable at 21 days of manufacture with particle sizes <100 nm. An in vivo comparison in mice of the immunogenicity to the cervical cancer peptide antigen HPV-16 E7 adjuvanted with CAF09b prepared by lipid film rehydration or microfluidics showed no difference between the formulations, indicating adjuvant activity is intact. Thus, it is possible to prepare suitable formulations of CAF09b by microfluidics.

Download Full-text

P673Moderate anti-tumor effect of the nanoliposomal anti-PCSK9 vaccine in BALB/c mice bearing colorectal cancer

European Heart Journal ◽

10.1093/eurheartj/ehz747.0279 ◽

2019 ◽

Vol 40 (Supplement_1) ◽

Author(s):

A A Momtazi-Borojeni ◽

M E Nik ◽

M R Jaafari ◽

M Banach ◽

A Sahebkar

Keyword(s):

Colon Cancer ◽

Tumor Size ◽

Ldl Receptor ◽

Positive Control ◽

Vaccine Group ◽

Size Analysis ◽

Control Group ◽

Lipid Film ◽

Protein Levels ◽

The Right

Abstract Background The higher levels of low-density lipoproteins (LDL) cholesterol (LDL-C) have been reported to correlate with higher prevalence and risk of colon cancer. Proprotein convertase subtilisin/kexin 9 (PCSK9) function, through reducing protein levels of liver LDL receptor, leads to elevated levels of plasma LDL-C. Purpose Here, we evaluated anti-tumor effect of nanoliposomal anti-PCSK9 vaccine in mice bearing colon carcinoma. Methods To formulate nanoliposomal anti-PCSK9 vaccine, liposome nanoparticles prepared by lipid-film hydration method were covalently attached to immunogenic PCSK9 peptide. The liposomal vaccine formulation was adsorbed to Alum adjuvant (L-IFPTA+) and injected subcutaneously four times with a bi-weekly interval in BALB/c mice. Two weeks after the last immunization, the vaccinated and unvaccinated mice were subcutaneously inoculated with CT26 colon cancer cells into the right flank. After tumor mass was palpable (approximately 10 mm3), the mice were randomly divided into three groups and involved to different treatments: (1) PBS (untreated control), (2) vaccine group, and (3) Doxil®(positive control) group which involved unvaccinated tumor-bearing mice who received Doxil®. To study therapeutic efficacy, mouse body weight, tumor size, and survival were monitored in a 3-day interval for 50 days. Results The nanoliposomal anti-PCSK9vaccine could efficiently induce specific antibodies against PCSK9 in BALB/c mice, and thereby reduce plasma level and function of PCSK9. Tumor size in the vaccinated mice was significantly lower than in Doxil and the control mice. Tumor size analysis revealed that time to reach endpoint (TTE) of the vaccine group was slightly but not significantly higher than that of Doxil and the control groups. The vaccinated mice survived slightly but not significantly longer than Doxil and the control mice. The vaccinated mice's life was prolonged by 24.4% as compared with the control mice, while it was increased by 9.8% in Doxil group (see Figure below). Conclusions Our findings declare that the nanoliposomal anti-PCSK9vaccine not only have no harmful effects, but also can mildly reduce tumor growth, and enhance live span and survival in mice bearing colon cancer.

Download Full-text